Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy

NEXT STORY
Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
PREV STORY
Short report of the status of the review in Oasmia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021

author_avatar
NASDAQ Market News

Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results

author_avatar
NASDAQ Market News

Kalytera Announces Initiation of Phase 2 Clinical Study in Prevention of Graft Versus Host Disease and Agreement with The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team

SAN FRANCISCO and TEL AVIV, Israel, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, ...

author_avatar
NASDAQ Market News